

# Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drugs in Development, 2021

<https://marketpublishers.com/r/G335719C1DC9EN.html>

Date: September 2021

Pages: 73

Price: US\$ 3,500.00 (Single User License)

ID: G335719C1DC9EN

## Abstracts

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drugs in Development, 2021

### SUMMARY

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucokinase - Drugs In Development, 2021, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage. The molecules developed by companies in Pre-Registration, Phase II and Preclinical stages are 1, 4 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes, Type 1 Diabetes (Juvenile Diabetes), Diabetes and Obesity.

Furthermore, this report also reviews key players involved in Glucokinase (Hexokinase

D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)

The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Overview

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Companies

Involved in Therapeutics Development

Eli Lilly and Co

Hua Medicine Shanghai Ltd

Impetis Biosciences Ltd

Kriya Therapeutics Inc

Ligand Pharmaceuticals Inc

Merck & Co Inc

Pfizer Inc

Sanwa Kagaku Kenkyusho Co Ltd

vTv Therapeutics Inc

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drug Profiles

dorzagliatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GKM-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KTA-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-2608204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-04937319 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 1 to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## TTP-399 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Dormant Products

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Discontinued Products

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Product

Development Milestones

Featured News & Press Releases

Apr 23, 2021: Hua Medicine announces acceptance of a New Drug Application for Dorzagliatin in China - First glucokinase activator (GKA) globally

Apr 13, 2021: vTv Therapeutics receives FDA breakthrough therapy designation for TTP399 for the treatment of type 1 diabetes

Apr 12, 2021: TTP399 SimpliciT-1 study results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin

Mar 23, 2021: vTv Therapeutics announces issuance of U.S. patent covering methods of treatment using TTP399

Mar 19, 2021: Milestone development achieved in clinical trials and commercialization, Hua medicine's dorzagliatin readying for NDA submission

Mar 18, 2021: vTv Therapeutics announces initiation of study evaluating TTP399's potential to reduce risk of diabetic ketoacidosis in patients with type 1 diabetes

Feb 23, 2021: vTv Therapeutics announces publication in diabetes care of results from SimpliciT-1 study of TTP399 in patients with type 1 diabetes

Dec 18, 2020: Hua Medicine successfully completed the Phase III registration clinical study and announced the 52-week results of the DAWN study (HMM0302) of the combined use of dozagliatin and metformin

Oct 14, 2020: Hua Medicine announces the drug manufacturing permit granted for Dorzagliatin

Sep 16, 2020: vTv Therapeutics to present additional positive clinical study results from phase 2 Simplici-T1 study of TTP399 as adjunctive therapy for patients with type 1 diabetes at EASD Virtual Meeting

Jul 01, 2020: Hua Medicine announces positive 24-week topline results of phase III metformin combination trial of dorzagliatin

Jun 18, 2020: Hua Medicine successfully completes SEED (HMM0301), Dorzagliatin's phase III Monotherapy trial

Jun 15, 2020: Hua Medicine's Dorzagliatin demonstrates improvements in  $\beta$ -Cell function in data presented at the American Diabetes Association's 80th Scientific Sessions

Jun 13, 2020: vTv Therapeutics presents two late-breaking poster sessions on Simplici-T1 study at the American Diabetes Association's Virtual Sessions supporting the potential of TTP399 as first-in-class oral adjunctive therapy for Type 1 Diabetes patients

May 31, 2020: Hua Medicine selected for inclusion in the MSCI Hong Kong Micro Cap Index

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2021  
Number of Products under Development by Therapy Areas, 2021  
Number of Products under Development by Indication, 2021  
Number of Products under Development by Companies, 2021  
Products under Development by Companies, 2021  
Number of Products under Investigation by Universities/Institutes, 2021  
Products under Investigation by Universities/Institutes, 2021  
Number of Products by Stage and Mechanism of Actions, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Pipeline by Eli Lilly and Co, 2021  
Pipeline by Hua Medicine Shanghai Ltd, 2021  
Pipeline by Impetis Biosciences Ltd, 2021  
Pipeline by Kriya Therapeutics Inc, 2021  
Pipeline by Ligand Pharmaceuticals Inc, 2021  
Pipeline by Merck & Co Inc, 2021  
Pipeline by Pfizer Inc, 2021  
Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, 2021  
Pipeline by vTv Therapeutics Inc, 2021  
Dormant Projects, 2021  
Discontinued Products, 2021



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

## I would like to order

Product name: Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/G335719C1DC9EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G335719C1DC9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

